XML 68 R56.htm IDEA: XBRL DOCUMENT
v3.22.4

License and Collaboration Agreements - Additional Information (Details) - USD ($) $ in Thousands |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | ---
Feb. 13, 2018 | Jul. 23, 2017 | Apr. 30, 2018 | Mar. 31, 2022 | Dec. 31, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Net expense reimbursements from collaboration partner |  |  |  |  |  |  | $ 21,400 |
Accounts receivable |  |  |  |  | $ 5,981 | $ 5,981 | 22,492 |
Bristol Myers Squibb Collaboration Agreement |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Accounts receivable |  |  |  |  | 4,200 | 4,200 |  |
Bristol-Myers Squibb | Purchase Agreement |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Shares issued (in shares) |  |  | 8,284,600 |  |  |  |  |
Sale of stock consideration received |  |  | $ 850,000 |  |  |  |  |
Other |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  | 40,000 | 40,000 |  |
Nektar 214 | Bristol-Myers Squibb |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Reimbursement of expenses |  |  |  |  | $ 20,800 |  |  |
Nektar 214 | Bristol-Myers Squibb | Research and Development |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Reimbursement of expenses |  |  |  | $ 24,900 |  | $ 45,700 | $ 101,500 | $ 128,200
Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Bristol-Myers Squibb |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Percentage of sharing production costs | 35.00% |  |  |  |  |  |  |
Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Bristol-Myers Squibb | Opdivo |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Percentage of sharing development costs | 67.50% |  |  |  |  |  |  |
Nektar-358 | Eli Lilly |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Percentage of sharing in Phase 2 development costs |  | 75.00% |  |  |  |  |  |
Nektar-358 | Eli Lilly And Company | Maximum |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Potential future additional development and regulatory milestones |  | $ 250,000 |  |  |  |  |  |
Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214 |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Percentage of sharing production costs | 65.00% |  |  |  |  |  |  |
Upfront and milestone payments received from license agreements |  |  | 1,000,000 |  |  |  |  |
Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Milestone One |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  | $ 50,000 |  |  |  |  |
Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Opdivo |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Percentage of sharing development costs | 32.50% |  |  |  |  |  |  |
Nektar's | Nektar-358 |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Received upfront and milestone payment |  | $ 150,000 |  |  |  |  |  |
Percentage of sharing in Phase 2 development costs |  | 25.00% |  |  |  |  |  |
Nektar's | Nektar-358 | Eli Lilly And Company |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Percentage of regulatory milestones payments will be reduced under certain conditions |  | 50.00% |  |  |  |  |  |
Percentage of regulatory milestones payments will be reduced if conditions occur |  | 75.00% |  |  |  |  |  |
Nektar's | Nektar-358 | Eli Lilly And Company | Maximum |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Percentage of funding phase 3 development costs on an indication by indication basis borne |  | 25.00% |  |  |  |  |  |

X
- Definition Net expense reimbursements from collaboration partner. + References No definition available. + Details
Name: | nktr_NetExpenseReimbursementsFromCollaborationPartner
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of development milestones payments, to be received, if conditions occur. + References No definition available. + Details
Name: | nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur
Namespace Prefix: | nktr_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of development milestones payments, to be received under certain conditions. + References No definition available. + Details
Name: | nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions
Namespace Prefix: | nktr_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of funding Phase three development costs on an indication by indication basis borne. + References No definition available. + Details
Name: | nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
Namespace Prefix: | nktr_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of sharing in development costs. + References No definition available. + Details
Name: | nktr_PercentageOfSharingInDevelopmentCosts
Namespace Prefix: | nktr_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of sharing in Phase 2 development costs. + References No definition available. + Details
Name: | nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts
Namespace Prefix: | nktr_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of sharing in production costs. + References No definition available. + Details
Name: | nktr_PercentageOfSharingInProductionCosts
Namespace Prefix: | nktr_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential development and regulatory milestones. + References No definition available. + Details
Name: | nktr_PotentialDevelopmentAndRegulatoryMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential development milestones. + References No definition available. + Details
Name: | nktr_PotentialDevelopmentMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Reimbursement of expenses. + References No definition available. + Details
Name: | nktr_ReimbursementOfExpenses
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sale of stock consideration received. + References No definition available. + Details
Name: | nktr_SaleOfStockConsiderationReceived
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront and milestone payments received from license agreements. + References No definition available. + Details
Name: | nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront and milestone payments received under license agreement. + References No definition available. + Details
Name: | nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644 + Details
Name: | us-gaap_SharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_OtherPartnerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=nktr_Nektar214Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_EliLillyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nktr_MilestoneAxis=nktr_MilestoneOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |